Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Eisai's Thyroid Cancer Drug Gets FDA Priority Review

October 15, 2014 10:45 am | News | Comments

Eisai Inc. announced that the FDA has accepted for review the NDA for its in-house developed agent lenvatinib mesylate as a treatment for progressive RAI-refractory DTC and granted the NDA Priority Review status. Read more...

TOPICS:

Clinical Conductor Takes Aim at Optimizing Oncology Clinical Trials

October 15, 2014 10:38 am | News | Comments

 The team behind Clinical Conductor is proud to announce brand new enhancements to the industry-leading CTMS. This first oncology focused release of several in the coming quarters adds a multitude of advanced features and functionalities designed to optimize the management and execution of oncology studies at organizations of all sizes and makeups.Read more...

TOPICS:

Selecta, JDRF, Sanofi Collaborate on SVP Immunotherapy for Type 1

October 15, 2014 10:31 am | News | Comments

Selecta Biosciences and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop an SVP immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. Read more...

TOPICS:
Advertisement

2nd Person Tests Positive for Ebola

October 15, 2014 10:21 am | by Emily Schmall and Nomaan Merchant | News | Comments

 A second Dallas hospital worker who provided care for the first Ebola patient diagnosed in the U.S. has tested positive for the disease, pointing to lapses beyond how one individual may have donned and removed personal protective garb. Read more...     

TOPICS:

Reversing Idiopathic Pulmonary Fibrosis

October 15, 2014 10:14 am | by Cynthia Fox, Science Editor | News | Comments

Lethal fibrosis in lungs of idiopathic pulmonary fibrosis (IPF) mouse models can be reversed, say Yale University researchers. Read more...                                      

TOPICS:

Combating Bladder Cancer With Approved Drug

October 14, 2014 1:53 pm | News | Comments

A drug that activates targets of the hedgehog signaling pathway, which is lost when bladder cancer invades, could prevent the progression of the disease in humans. Clinical trials are planned. Read more...                  

TOPICS:

Medtronic Begins Study of First Predictive Low Glucose Management Technology

October 14, 2014 1:39 pm | News | Comments

Medtronic Inc. announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. Read more...

TOPICS:

Rats of New York and The Diseases They Carry

October 14, 2014 12:29 pm | News | Comments

In the first study to look at would-be diseases carried by New York City rats, scientists at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health identified bacterial pathogens, including E. coli, Salmonella, and C. difficile, that cause mild to life-threatening gastroenteritis in people. Read more...

TOPICS:
Advertisement

Biologists Find Gene That Could Stop Tumors in Their Tracks

October 14, 2014 12:21 pm | News | Comments

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers. Read more...                                         

TOPICS:

Astellas Collaborates with Harvard for Retinal Degeneration Treatment

October 14, 2014 12:13 pm | News | Comments

Astellas Pharma Inc. announced a research collaboration with an investigator at Harvard focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets. Read more...

TOPICS:

Rare Genetic Disease Protects Against Bipolar Disorder

October 14, 2014 12:01 pm | News | Comments

A team of scientists led by researchers at the UMass Medical School and UMMSM have identified what is likely a key genetic pathway underlying bipolar disorder, a breakthrough that could lead to better drugs for treating bipolar affective disorder, as well as depression and other related mood disorders. Read more...

TOPICS:

10,000 New Ebola Cases Per Week Could Be Seen

October 14, 2014 11:26 am | by Maria Cheng, AP Medical Writer - Associated Press | News | Comments

West Africa could see up to 10,000 new Ebola cases a week within two months, the World Health Organization said, also confirming the death rate in the current outbreak has risen to 70%. Read more...                                      

TOPICS:

C3BS Enrolls Patients in Switzerland in its Phase 3 Clinical Trial Chart-1

October 14, 2014 10:39 am | News | Comments

C3BS, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announced it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase 3 trial for C-Cure in Switzerland. Read more...

TOPICS:

Chemical Derived from Broccoli Sprouts Shows Promise in Treating Autism

October 14, 2014 10:27 am | News | Comments

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs). Read more...

TOPICS:

Researchers Treat Pulmonary Hypertension Through the Leaves of Plants

October 14, 2014 10:18 am | News | Comments

Researchers at the University of Pennsylvania and the University of Florida have identified a drug that can be used to treat pulmonary hypertension, a disease for which few therapy options exist. Read more...                            

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading